Mizuho raised the firm’s price target on Nurix Therapeutics (NRIX) to $30 from $24 and keeps an Outperform rating on the shares. The key opinion leader with which the firm hosted a call at the ASH meeting believes Nurix’s bexobrutideg is shaping up to have a more favorable profile than BeOne Medicines’ (ONC) BGB-16673, reports the analyst.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics price target raised to $31 from $28 at H.C. Wainwright
- Balanced Outlook on Nurix Therapeutics: Promising Developments Amid Uncertainties
- Nurix Therapeutics price target raised to $30 from $27 at BTIG
- Nurix Therapeutics Reports Promising Data at Hematology Meeting
- Nurix Therapeutics presents data from Phase 1 trial of bexobrutideg